Breaking News Instant updates and real-time market news.

ANAB

AnaptysBio

$71.18

5.26 (7.98%)

, REGN

Regeneron

$415.32

3.22 (0.78%)

11:50
03/12/19
03/12
11:50
03/12/19
11:50

AnaptysBio jumps after JPMorgan surveys doctors on asthma data

Shares of AnaptysBio (ANAB) are higher after JPMorgan analyst Anupam Rama asked 60 U.S. physicians about the company's Phase 2a eosinophilic asthma data for etokimab. While acknowledging the data for etokimab are early stage, Rama told investors earlier in a research note that he is "broadly encouraged" by the enthusiasm of the surveyed physicians. Regeneron's (REGN) cautious commentary on monotherapy activity of its IL-33 antibody, REGN3500, has emerged as an overhang on AnaptysBio's etokimab asthma program, but anecdotal feedback in the survey suggests IL-33 inhibition is viewed as an "interesting mechanism," Rama wrote. He sees a "number of potential value creating catalysts" for AnaptysBio shares in mid-2019, including Phase 2b data of etokimab in atopic dermatitis, Phase 2 data of etokimab in chronic rhinosinusitis with nasal polyps, and Phase 2 data from ANB019 in generalized pustular psoriasis. The analyst keeps an Overweight rating on AnaptysBio. The stock in late morning trading is up 9%, or $6.05, to $71.99 in late morning trading.

ANAB

AnaptysBio

$71.18

5.26 (7.98%)

REGN

Regeneron

$415.32

3.22 (0.78%)

  • 28

    Apr

  • 13

    May

ANAB AnaptysBio
$71.18

5.26 (7.98%)

11/21/18
11/21/18
INITIATION
Target $115

Overweight
JPMorgan sees attractive entry point, starts AnaptysBio at Overweight
As previously reported, JPMorgan analyst Anupam Rama started AnaptysBio with an Overweight rating and $115 price target, stating that he sees an attractive entry point with the stock down over 35% since early October. The company's proprietary antibody development approach has been validated by both data and partnerships, while its lead asset etokimab has delivered positive early-stage data in both atopic dermatitis and eosinophilic asthma, Rama tells investors.
12/20/18
HCWC
12/20/18
INITIATION
Target $126
HCWC
Buy
AnaptysBio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started AnaptysBio with a Buy rating and $126 price target. While the company "emerges as a newcomer in the competitive field of inflammatory diseases," it may differentiate itself with a "double play of two wholly owned assets (novel targets) and a proprietary antibody platform," Fein tells investors in a research note. AnaptysBio is "studded with" two clinical stage biologics, five ongoing clinical programs, two licensing partners, and an array of data readouts in the next 12-18 months, says the analyst.
01/18/19
RHCO
01/18/19
NO CHANGE
Target $125
RHCO
Buy
AnaptysBio price target lowered to $125 from $156 at SunTrust
SunTrust analyst Joon Lee lowered his price target on AnaptysBio to $125, citing increasing competition for its product. The analyst keeps his Buy rating however and expects its stock to show "significant upside from current levels in 2019" ahead of the four major data readouts to follow "already promising" phase 2 proof of concept data in atopic dermatitis and asthma. Lee is overall positive on AnaptysBio's "proprietary antibody generation platform that is able to mimic natural in vivo process of antibody diversity generation in an in vitro system".
02/22/19
GUGG
02/22/19
INITIATION
Target $135
GUGG
Buy
AnaptysBio initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated AnaptysBio with a Buy rating and $135 price target, calling its lead asset, etokimab, a "a pipeline-in-a-product with blockbuster potential" given its potential for broad applicability across multiple atopic diseases.
REGN Regeneron
$415.32

3.22 (0.78%)

02/25/19
PIPR
02/25/19
NO CHANGE
Target $475
PIPR
Overweight
Verdict upholding Amgen patent should not impact Regeneron, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $475 price target on Regeneron (REGN), saying that today's verdict upholding the validity of two Amgen (AMGN) patents should not matter much because U.S. Praluent represents just $12 per share in its valuation. The analyst adds that Regeneron still has "several procedural steps to execute in the coming months aiming to change the verdict or request another new trial", and that today's decision marks the second time that a jury ruled in Amgen's favor.
02/26/19
PIPR
02/26/19
NO CHANGE
Target $487
PIPR
Overweight
Regeneron price target raised to $487 from $475 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Regeneron Pharmaceuticals to $487 after adjusting his Dupixent model to include impact of label expansion into adolescent atopic dermatitis and chronic rhinosinusitis with nasal polyps. Dupixent's clinical profile "continues to impress" in showing meaningful, statistically significant improvements across a host of measures including sinus opacification and systemic corticosteroid use, Raymond tells investors in a research note. The analyst keeps an Overweight rating on Regeneron.
02/26/19
MSCO
02/26/19
NO CHANGE
Target $215
MSCO
Overweight
Morgan Stanley says Sanofi, Regeneron face 'uphill battle' in Amgen patent fight
After a Delaware district court ruled in favor of Amgen (AMGN) upholding the validity of patents on PCSK9 antibodies in litigation versus Sanofi (SNY) and Regeneron (REGN), Morgan Stanley analyst Matthew Harrison said he believes Sanofi and Regeneron face an "uphill battle" given this was the second district court trial to find in favor of Amgen. Harrison, who said he expects "no acute impact" to Amgen or Regeneron shares given the limited recent investor focus on PCSK9 uptake, keeps an Overweight rating on Amgen shares.
02/26/19
JEFF
02/26/19
NO CHANGE
JEFF
The Medicines Co. may have only PCSK9 not infringing Amgen, says Jefferies
Following yesterday's patent win over Sanofi (SNY) and Regeneron (REGN), Amgen (AMGN) now possesses broad patents which will be difficult for most competitors to circumvent, Jefferies analyst Biren Amin tells investors in a research note. The Medicines Co.'s (MDCO) inclisiran, which falls outside of the claims as a purely RNA-directed agent, could be the only PCSK9 mechanism which does not infringe Amgen's Repatha, Amin contends. He believes that should Sanofi and Regeneron's Praluent be hit with a permanent injunction, inclisiran is "well positioned to carve out market share in a growing PCSK9 class."

TODAY'S FREE FLY STORIES

EADSY

Airbus

$0.00

(0.00%)

15:42
06/18/19
06/18
15:42
06/18/19
15:42
Periodicals
Airbus eyes new partners to expand in U.S. space market, Reuters says »

Airbus' defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$19.33

0.57 (3.04%)

15:41
06/18/19
06/18
15:41
06/18/19
15:41
Conference/Events
Amarin management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 28

    Sep

Z

Zillow

$46.52

0.44 (0.95%)

15:40
06/18/19
06/18
15:40
06/18/19
15:40
Options
Zillow option volume double normal on 5way on Amex adjusting long calls »

Zillow option volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.67

0.54 (1.49%)

15:39
06/18/19
06/18
15:39
06/18/19
15:39
Options
Calls lead puts 3:1 in General Motors with focus on 3day upside »

Calls lead puts 3:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 12

    Aug

15:25
06/18/19
06/18
15:25
06/18/19
15:25
General news
Treasury Market Summary »

Treasury Market Summary:…

LZB

La-Z-Boy

$29.90

-0.33 (-1.09%)

15:19
06/18/19
06/18
15:19
06/18/19
15:19
Options
La Z Boy options imply 13.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
06/18/19
06/18
15:17
06/18/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
06/18/19
06/18
15:16
06/18/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$7.71

0.09 (1.18%)

15:15
06/18/19
06/18
15:15
06/18/19
15:15
Options
McDermott put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$27.59

0.64 (2.37%)

15:12
06/18/19
06/18
15:12
06/18/19
15:12
Hot Stocks
Fifth Third jumps almost 2.5% after raising dividend, new 100M buyback »

Shares of Fifth Third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

JBL

Jabil

$27.45

0.655 (2.44%)

15:04
06/18/19
06/18
15:04
06/18/19
15:04
Options
Jabil Circuit options imply 11.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

14:55
06/18/19
06/18
14:55
06/18/19
14:55
General news
FOMC forecast preview: »

FOMC forecast preview:…

APC

Anadarko

$70.00

0.21 (0.30%)

14:52
06/18/19
06/18
14:52
06/18/19
14:52
Periodicals
Anadarko gives go-ahead on $20B LNG export project in Mozambique, Reuters says »

Anadarko Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSP

E.W. Scripps

$15.02

0.01 (0.07%)

, CBS

CBS

$49.38

0.22 (0.45%)

14:50
06/18/19
06/18
14:50
06/18/19
14:50
Hot Stocks
E.W. Scripps reports consent decree to settle DOJ civil case »

In a regulatory filing,…

SSP

E.W. Scripps

$15.02

0.01 (0.07%)

CBS

CBS

$49.38

0.22 (0.45%)

FOXA

Fox Corp.

$36.59

0.44 (1.22%)

FOX

Fox Corp.

$36.23

0.44 (1.23%)

TGNA

Tegna

$15.09

0.22 (1.48%)

SBGI

Sinclair Broadcast

$53.51

0.01 (0.02%)

NXST

Nexstar

$102.72

2.31 (2.30%)

MDP

Meredith

$53.04

0.88 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 25

    Jun

  • 06

    Aug

  • 08

    Aug

  • 13

    Nov

WFC

Wells Fargo

$46.25

0.99 (2.19%)

, GS

Goldman Sachs

$195.72

4.98 (2.61%)

14:50
06/18/19
06/18
14:50
06/18/19
14:50
Periodicals
Wells Fargo dismissed from VRDO lawsuit, Reuters reports »

Wells Fargo & Co…

WFC

Wells Fargo

$46.25

0.99 (2.19%)

GS

Goldman Sachs

$195.72

4.98 (2.61%)

JPM

JPMorgan

$111.21

2.01 (1.84%)

BAC

Bank of America

$28.72

0.79 (2.83%)

BCS

Barclays

$7.59

0.09 (1.20%)

C

Citi

$68.12

1.59 (2.39%)

RY

Royal Bank of Canada

$78.69

1.45 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 09

    Jul

  • 13

    Jul

  • 13

    Jul

  • 15

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

  • 13

    Aug

  • 21

    Aug

  • 12

    Oct

ADBE

Adobe

$278.26

2.67 (0.97%)

14:49
06/18/19
06/18
14:49
06/18/19
14:49
Options
Adobe options imply 5.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

RARX

RA Pharmaceuticals

$22.36

-0.38 (-1.67%)

14:48
06/18/19
06/18
14:48
06/18/19
14:48
Recommendations
RA Pharmaceuticals analyst commentary  »

RA Pharmaceuticals price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

FITB

Fifth Third

$27.53

0.58 (2.15%)

14:46
06/18/19
06/18
14:46
06/18/19
14:46
Hot Stocks
Fifth Third boosts quarterly dividend 9% to 24c »

Fifth Third Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

MAS

Masco

$38.12

0.22 (0.58%)

14:42
06/18/19
06/18
14:42
06/18/19
14:42
Recommendations
Masco analyst commentary  »

Masco sale of cyclical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$31.69

0.82 (2.66%)

14:25
06/18/19
06/18
14:25
06/18/19
14:25
Options
Skechers call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLT

Poly

$44.03

0.98 (2.28%)

14:25
06/18/19
06/18
14:25
06/18/19
14:25
Conference/Events
Poly participates in an investor webinar with Northland Capital Markets »

Northland Capital Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

  • 28

    Jun

  • 13

    Nov

14:25
06/18/19
06/18
14:25
06/18/19
14:25
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Subcommittee on…

GIII

G-III Apparel

$26.38

0.71 (2.77%)

14:18
06/18/19
06/18
14:18
06/18/19
14:18
Hot Stocks
G-III Apparel up 6% after CEO buys over $1M worth of shares »

G-III Apparel Group CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 09

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
06/18/19
06/18
14:17
06/18/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
06/18/19
06/18
14:16
06/18/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.